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Synergistic Effect of the
Combination of Ranolazine and
Dronedarone to Suppress Atrial Fibrillation
Alexander Burashnikov, PHD,* Serge Sicouri, MD,* José M. Di Diego, MD,* Luiz Belardinelli, MD,†
Charles Antzelevitch, PHD*
Utica, New York; and Palo Alto, California
Objectives The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in sup-
pression of atrial fibrillation (AF).
Background Safe and effective pharmacological management of AF remains one of the greatest unmet medical needs.
Methods The electrophysiological effects of dronedarone (10 mol/l) and a relatively low concentration of ranolazine
(5 mol/l) separately and in combination were evaluated in canine isolated coronary-perfused right and left
atrial and left ventricular preparations as well as in pulmonary vein preparations.
Results Ranolazine caused moderate atrial-selective prolongation of action potential duration and atrial-selective depres-
sion of sodium channel–mediated parameters, including maximal rate of rise of the action potential upstroke,
leading to the development of atrial-specific post-repolarization refractoriness. Dronedarone caused little or no
change in electrophysiological parameters in both atrial and ventricular preparations. The combination of drone-
darone and ranolazine caused little change in action potential duration in either chamber but induced potent
use-dependent atrial-selective depression of the sodium channel–mediated parameters (maximal rate of rise of
the action potential upstroke, diastolic threshold of excitation, and the shortest cycle length permitting a 1:1
response) and considerable post-repolarization refractoriness. Separately, dronedarone or a low concentration of
ranolazine prevented the induction of AF in 17% and 29% of preparations, respectively. In combination, the
2 drugs suppressed AF and triggered activity and prevented the induction of AF in 9 of 10 preparations (90%).
Conclusions Low concentrations of ranolazine and dronedarone produce relatively weak electrophysiological effects and
weak suppression of AF when used separately but when combined exert potent synergistic effects, resulting in
atrial-selective depression of sodium channel–dependent parameters and effective suppression of AF. (J Am
Coll Cardiol 2010;56:1216–24) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.600a
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strial fibrillation (AF) is the most frequently encountered
ustained clinical arrhythmia and is associated with signifi-
ant morbidity and mortality. The efficacy and/or safety of
urrently available anti-AF drugs is less than optimal.
miodarone remains the best available anti-AF agent for
he long-term maintenance of sinus rhythm. Long-term use
f amiodarone, however, is often associated with extracar-
iac toxicity. Dronedarone, a noniodinated derivative of
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ccepted August 17, 2010.miodarone, has a better safety profile, although its anti-AF
fficacy in the clinic is inferior to that of amiodarone (1).
fter numerous large clinical trials (2–5), the U.S. Food and
rug Administration approved dronedarone for the man-
gement of patients with AF without severe heart failure.
In experimental studies involving canine isolated atria,
eparate application of ranolazine and long-term amioda-
one has been shown to exert atrial-selective depression of
odium channel current (INa)-dependent parameters and to
ffectively suppress AF (6–10). The combination of long-
erm amiodarone and acute ranolazine (5 mol/l) caused
arked atrial-selective depression of INa-dependent param-
ters and was very effective in suppressing AF (11). Because
hysicians are reticent to use amiodarone because of its
dverse effects, we sought to determine whether a similar
ynergism exists between ranolazine and dronedarone. The
resent study was designed to test the hypothesis that a
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October 5, 2010:1216–24 Combination of Ranolazine and Dronedarone for AFombination of acute dronedarone and a low concentration of
anolazine acts synergistically to cause potent atrial-selective
lectrophysiological actions that lead to the effective suppres-
ion and prevention of atrial arrhythmias.
ethods
xperiments were performed using isolated coronary-
erfused canine right atrial (RA) and left ventricular (LV)
reparations as well as superfused pulmonary vein (PV)
leeve preparations. Transmembrane action potential (AP)
ecordings were obtained using standard or floating glass
icroelectrodes. A pseudo-electrocardiogram was recorded
sing 2 electrodes consisting of silver/silver chloride half
ells placed in the Tyrode’s solution bathing the prepara-
ion, 1.0 to 1.2 cm from the 2 opposite sides of the atrial or
entricular coronary-perfused preparations. The diastolic
hreshold of excitation (DTE) was determined by increasing
timulus intensity in 0.01-mA steps. The effective refractory
eriod (ERP) was measured by delivering premature stimuli
fter every 10th regular beat at a pacing cycle length (CL) of
00 ms (with 10-ms resolution; stimulation with a 2  DTE
mplitude, determined at each CL). Post-repolarization
efractoriness (PRR) was recognized when ERP exceeded
P duration (APD) measured at 90% repolarization in the
entricles and APD measured at 70% repolarization in the
tria. Note that ventricular ERP coincided with APD
easured at 90% repolarization, whereas atrial ERP gener-
lly coincided with APD measured at 70% to 75% repolar-
zation. The anti-AF efficacy of dronedarone and ranolazine
eparately as well as in combination was tested in an
cetylcholine (ACh)–mediated model of persistent AF.
ersistent ACh-induced AF was inducible in 100% of
anine coronary-perfused RA preparations.
Detailed methods, experimental protocols, and statistical
pproaches are included in the online supplement.
esults
lectrophysiological effects of ranolazine and dronedarone.
anolazine (5 mol/l) and dronedarone (10 mol/l)
lone as well as combined caused little or no change in
PD in either RA or LV coronary-perfused preparations
Figs. 1A and 1B). When applied separately, both ranola-
ine (5 mol/l) and dronedarone (10 mol/l) prolonged the
RP more than APD measured at 70% repolarization in the
tria, thus leading to the development of PRR (Fig. 1B).
he extent of the atrial PRR was greater after ranolazine
han dronedarone. Ventricular ERP was not altered by
ither ranolazine or dronedarone at the concentrations
ested. The combination of dronedarone and ranolazine
aused a significant synergistic prolongation of ERP in the
tria but did not change ERP in ventricles, thus resulting in
marked atrial-specific PRR (Fig. 1B). tAt a pacing CL of 500 ms, the
aximal rate of rise of the action
otential upstroke (Vmax) was re-
uced by ranolazine (5 mol/l)
nd by dronedarone (10 mol/l)
n RA but not in LV prepara-
ions (Fig. 2). At this pacing rate,
he combination of these agents
ed to a reduction of Vmax in both
tria and ventricles but predom-
nantly in the former (27  11%
s. 12  28% decrease, respec-
ively). In the atria, acceleration
f pacing rate from a CL of 500
o 300 ms caused a much greater
epression of Vmax when drone-
arone and ranolazine were com-
ined than when each of these
gents was applied alone (Fig. 2).
n the ventricles, a similar accel-
ration of pacing rate led to only
modest reduction in Vmax un-
er all conditions tested.
In PV sleeves, a change of
ate from a CL of 5,000 ms to a
L of 300 ms caused a 13  3%
eduction in Vmax under control conditions and 19  4%,
0 3%, and 50 9% reductions after ranolazine (5 mol/l),
ronedarone (10 mol/l), and dronedarone plus ranolazine,
espectively (Fig. 3).
The shortest S1 to S1 interval permitting 1:1 activation
as increased by ranolazine in RA preparations preferen-
ially, but not by dronedarone in either RA or LV prepa-
ations (Fig. 4A). When dronedarone and ranolazine were
ombined, the shortest S1 to S1 interval was significantly
ncreased in all preparations, but the change was many times
reater in atrial (RA and PV sleeves) than in ventricular
reparations. The DTE was not significantly affected by
ither ranolazine (5 mol/l) or dronedarone (10 mol/l) in
ither atrial or ventricular preparations (Fig. 4B). How-
ver, when these drugs were combined, the DTE was
ncreased significantly in RA and PV sleeves, but not in
V preparations.
ntiarrhythmic effects in coronary-perfused atria and
uperfused PV sleeves. Persistent AF was induced in
00% of coronary-perfused atrial preparations in the pres-
nce of 1 mol/l ACh (6). Dronedarone (10 mol/l) and a
ow concentration of ranolazine (5 mol/l) were poorly
ffective in preventing the induction of persistent ACh-
ediated AF and in terminating persistent AF when
dministered separately (Fig. 5, Tables 1 and 2). However,
hen dronedarone (10 mol/l) and ranolazine (5 mol/l)
ere combined, the success rate for preventing the induc-
ion of persistent AF was dramatically augmented to 90% (9
f 10 atrial preparations) (Table 1). The drug combination
Abbreviations
and Acronyms
ACh  acetylcholine
AF  atrial fibrillation
AP  action potential
APD  action potential
duration
CL  cycle length
DAD  delayed
afterdepolarization
DTE  diastolic threshold
of excitation
ERP  effective refractory
period
INa  sodium channel
current
LV  left ventricular
PRR  post-repolarization
refractoriness
PV  pulmonary vein
RA  right atrial
Vmax  maximal rate of rise
of the action potential
upstrokeerminated persistent AF in 6 of 10 atria (Table 2) and
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Combination of Ranolazine and Dronedarone for AF October 5, 2010:1216–24revented the reinduction of AF in 100% of preparations (6
f 6). Persistent atrial flutter or tachycardia (with a CL
160 ms) could be induced by rapid pacing and/or pro-
rammed electrical stimulation in 2 of the 6 preparations.
Delayed afterdepolarization (DAD)–induced triggered
ctivity induced in PV sleeves was reduced by ranolazine
mol/l and dronedarone 10 mol/l and abolished when
he drugs were combined (6 of 6) (Fig. 6).
iscussion
ur data demonstrate a potent atrial-selective effect of the
ombination of dronedarone (10 mol/l) and ranolazine
5 mol/l) to depress sodium channel– dependent param-
ters and to suppress AF and triggered activity in experi-
ental models of AF. When dronedarone (10 mol/l) or
anolazine (5 mol/l) was used alone, the observed electro-
hysiological changes in both atria and ventricles were
ither small or absent, and the anti-AF efficacy of the drug
as poor (30%). Considering the relatively good safety
rofiles of both agents, our results suggest that the striking
ynergistic atrial-selective action of ranolazine and drone-
arone may offer a unique combination therapy for AF that
Figure 1 Synergistic Effect of Ranolazine and Dronedarone to A
Atrial-selective induction of post-repolarization refractoriness (PRR) by ranolazine (R
difference between the effective refractory period [ERP] and the action potential d
and the action potential duration measured at 90% repolarization [APD90] in th
cles). (A) Superimposed action potentials demonstrating relatively small changes
selective induction of PRR. Ventricular data were obtained from epicardium and at
control (C). †p  0.05 versus washout. ‡p  0.05 versus Dron 10 mol/l. #p0
and Dron (from washout) versus the sum of changes caused by Ran and Dron inds both safe and effective. alectrophysiology and antiarrhythmic efficacy of dronedarone.
cute dronedarone has been reported to produce variable
ut a generally small or no effect to alter APD (12–16). In
abbit superfused cardiac preparations, acute dronedarone
bbreviated APD in both atria and ventricles (14,15). APD
as not altered in superfused ventricular preparations iso-
ated from canine and guinea pig hearts at concentrations of
ronedarone up to 10 mol/l (12,13). Thus, our data on the
cute effect of dronedarone on APD are generally consistent
ith those reported previously.
Ventricular and atrial ERP have been reported to be
rolonged to a similar extent after acute dronedarone in
ogs in vivo (17). In our present in vitro investigation,
ronedarone prolonged both atrial and ventricular ERP,
ith preferential lengthening in the atria (9% and 4%,
espectively). ERP prolongation by dronedarone and rano-
azine in the ventricles was associated with a comparable
rolongation of APD measured at 90% repolarization (Fig. 1). In
ontrast, the increase of ERP in the atria greatly exceeded the
ncrease in APD measured at 70% repolarization, because of the
evelopment of marked PRR.
Acute dronedarone (10 mol/l) has been reported to
roduce no changes or a relatively small reduction in AP
max in both atrial and ventricular rabbit superfused prep-
Selectively Induce PRR
nd dronedarone (Dron) alone and in combination (PRR was approximated by the
n measured at 70% repolarization [APD70] in the atria and between the ERP
ricles; ERP corresponds to APD70–75 in the atria and to APD90 in the ventri-
ronedarone and ranolazine and their combination. (B) Summary data of atrial-
ta from endocardial pectinate muscle (n  7 to 8). *p  0.05 versus respective
rsus respective ERP. **p  0.05, change in ERP induced by combination of Ran
ntly (both from washout). Cycle length  500 ms.trial-
an) a
uratio
e vent
with d
rial da
.05 ve
ependerations as well as in canine and guinea pig ventricular and
1219JACC Vol. 56, No. 15, 2010 Burashnikov et al.
October 5, 2010:1216–24 Combination of Ranolazine and Dronedarone for AFFigure 2 Synergistic Effect of Ranolazine and Dronedarone to Atrial-Selectively Depress Vmax
Atrial-selective synergetic depression of the maximal rate of rise of the action potential (AP) upstroke (Vmax) by the combination of dronedarone (Dron) and ranolazine
(Ran) at rapid activation rates. Shown are AP tracings and corresponding Vmax values recorded during acceleration of pacing rate from a cycle length (CL) of 500 to 300
ms in atrial (A) and ventricular (B) perfused preparations. Composite data of Vmax of atrial and ventricular preparations paced at a CL of 500 ms (C, left) expressed as
percentage of control (C). Composite data of Vmax of atrial and ventricular APs after acceleration from a CL of 500 to 300 ms expressed as percentage of Vmax value
recorded at a CL of 500 ms in controls (C, right). “Atria” represent combined pectinate muscle and crista terminalis data. “Ventricles” represent combined epicardial
and M-cell data from ventricular wedge preparations (n  7 to 8). *p  0.05 versus respective control. †p  0.05 versus washout. ‡p  0.05 versus Dron 10 mol/l.
#p  0.05 versus respective atrial values. **p  0.01, change in Vmax induced by the combination of Ran and Dron (from washout) versus the sum of changes caused
by Ran and Dron independently (both from washout).
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Combination of Ranolazine and Dronedarone for AF October 5, 2010:1216–24urkinje fiber superfused preparations (12,13,15). Even at
apid pacing rates (a CL of 125 ms), dronedarone 10 mol/l
educed the AP Vmax by only 16% in superfused rabbit atrial
reparations (15). Thus, our data showing a modest effect of
cute dronedarone on AP Vmax are consistent with those
reviously reported.
Interestingly, although several clinical investigations have
eported on the anti-AF efficacy of dronedarone for the
ong-term maintenance of sinus rhythm (2,3), we could not
nd a full-length report evaluating the efficacy of droneda-
one against AF in any experimental model (acutely or long
erm). We are also not aware of any clinical study testing the
nti-AF effect of acute dronedarone. Thus, we are unable to
ompare our results of the relatively weak actions of acute
ronedarone to suppress AF with any previous preclinical or
linical study.
Available clinical data indicate that the long-term efficacy
f dronedarone for the maintenance of sinus rhythm in AF
atients is inferior to that of amiodarone (1). In the
IONYSOS (Efficacy and Safety of Dronedarone Versus
miodarone for the Maintenance of Sinus Rhythm in
atients With Atrial Fibrillation) trial, a direct comparison
etween amiodarone and dronedarone showed that the rate
Figure 3 Synergistic Effect of Ranolazine and Dronedarone to D
Synergistic effect of the combination of ranolazine and dronedarone on maximal ra
monary vein (PV) sleeve preparations. (A) Vmax traces recorded after a change in c
changes after acceleration of pacing rate from a CL of 5,000 to 300 ms (n  4 to
**p  0.05, change in Vmax induced by combination ranolazine plus dronedarone
independently (both from washout).f recurrence of AF was 63% with dronedarone and 42% pith amiodarone (at 6-month follow-up). In the combined
URIDIS (European Trial in Atrial Fibrillation or Flutter
atients Receiving Dronedarone for the Maintenance of
inus Rhythm) and ADONIS (American-Australasian
rial With Dronedarone in Atrial Fibrillation or Flutter
atients for the Maintenance of Sinus Rhythm), AF recur-
ence occurred in 64% of patients treated with dronedarone
ompared with 75% patients taking placebo at 1-year
ollow-up (3). The rate of conversion of persistent AF with
ronedarone ranged from 5.8% to 14.8% (800 to 1,600
g/day) versus 3.1% in the placebo arm, as determined on
he fifth to seventh days after the start of drug treatment (2).
he relatively weak actions of acute dronedarone to suppress
F in the present study are consistent with the modest
ffects of the drug on AF in the clinic.
lectrophysiology and antiarrhythmic efficacy of ranolazine.
e have previously reported that ranolazine 5 mol/l
auses moderate electrophysiological effects in canine
trial preparations, with little to no effect in ventricular
reparations (6,18). This concentration of ranolazine is well
ithin the therapeutic range of the drug (2 to 10 mol/l).
anolazine has also been shown to cause predominant atrial
ss Vmax in PV
rise of the action potential upstroke (Vmax) after an abrupt change in rate in pul-
ngth (CL) from 5,000 to 300 ms. (B) Graph displaying composite data of Vmax
p  0.05 versus control. †p  0.05 versus ranolazine or dronedarone alone.
washout) versus the sum of changes caused by ranolazine and dronedaroneepre
te of
ycle le
8). *
(fromrolongation of ERP in anesthetized closed-chest pigs (10).
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October 5, 2010:1216–24 Combination of Ranolazine and Dronedarone for AFThe anti-AF efficacy of ranolazine 5 mol/l was not
ested in the ACh-mediated AF model in our previous
tudies. Higher concentrations of ranolazine (10 mol/l), at
Figure 4 Synergistic Effect of Ranolazine and Dronedarone to A
Effect of ranolazine (Ran) (5 mol/l), dronedarone (Dron) (10 mol/l), and their comb
the diastolic threshold of excitation (DTE). The combination of Dron and Ran caused g
*p  0.05 versus respective control (C). †p  0.05 versus washout and Dron. ‡p 
caused by combination of ranolazine and dronedarone (relative to washout) versus the
Figure 5 Effect of Dronedarone and Ranolazine to Suppress AF
The combination of dronedarone (10 mol/l) and ranolazine (5 mol/l) is
effective in terminating persistent atrial fibrillation (AF) and/or preventing its
induction in coronary-perfused right atria. (A) Persistent acetylcholine (ACh)
(0.5 mol/l)–mediated AF is terminated by the drug combination. AF is initially
converted to flutter and then to sinus rhythm. (B) The combination of dronedar-
one and ranolazine prevents rapid-pacing induction of AF after pretreatment
with ACh (1 mol/l), likely because of depression of the sodium channel (see
reduction of maximal rate of rise of the action potential [AP] upstroke). Acceler-
ation of pacing rate from a cycle length (CL) of 500 to 130 ms leads to failure
of a 1:1 response. ECG  electrocardiogram.the upper end of the therapeutic range, were shown to exert
otent anti-AF effects in experimental models of vagally
ediated AF in canine atria in vitro (10 mol/l) (6) and
orcine atria in vivo (about 9 mol/l plasma concentration)
10) models. In an ischemia-reperfusion-isoproterenol
odel of AF, ranolazine 5 mol/l was observed to prevent
he induction of AF in 60% of atrial preparations (6). In
uperfused PV preparations ranolazine 10 mol/l effectively
uppressed intracellular calcium-dependent DAD and late
hase 3 early afterdepolarization–induced triggered activity
8). Consistent with results of our in vitro experimental
odels of AF, ranolazine has also been shown to reduce the
nset of new AF and to terminate AF in the clinic (19–21).
Ranolazine’s antiarrhythmic action in the ventricle is
hought to be due largely to its potent inhibition of late INa,
hich serves to normalize abnormal repolarization encoun-
ered under pathophysiologic conditions (18). In contrast,
he anti-AF efficacy of ranolazine is ascribed to its potent
trial-selective inhibition of early INa (6). Although not the
redominant mechanism, blockade of late INa likely con-
ributes to ranolazine’s antiarrhythmic action in the atria.
rug combination for antiarrhythmic therapy: efficacy
nd safety. The concept of combining dronedarone and
anolazine in the management of AF derives from our
ecent demonstration of a synergetic effect of a combination
f chronic amiodarone and acute ranolazine (11). This
ombination was found to depress INa-dependent parame-
ers, thus acting to terminate and prevent the reinduction of
F in coronary-perfused canine atrial preparations as well as
o suppress DAD-induced and early afterdepolarization–
nduced triggered activity in PVs (11). Ectopic activity
rising from the PV has been shown to play a prominent
ole in the development of AF (22). Early afterdepolariza-
ion–induced as well as DAD-induced triggered activity
riginating from PV sleeves has been proposed as a potential
Selectively Depress Excitability
to prolong the shortest cycle length (CL) permitting 1:1 activation and to increase
changes in these parameters in atrial than in ventricular preparations (n  4 to 8).
ersus Ran. #p  0.001 versus respective atrial values. **p  0.05, change in Vmax
of changes induced by ranolazine and dronedarone independently.trial-
ination
reater
0.05 v
sumrigger in the initiation of AF (9,23,24). When dronedarone
(
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Combination of Ranolazine and Dronedarone for AF October 5, 2010:1216–245 to 10 mol/l) or ranolazine (5 mol/l) is used separately,
AD-induced triggered activity is reduced but is totally
bolished when the drugs are used in combination.
The rationale for the amiodarone-ranolazine combina-
ion stemmed from the observation that both agents are
trial-selective sodium-channel blockers (6,7) and that ami-
darone is a predominantly inactivated-state blocker of the
odium channel, and ranolazine is a predominantly open-
tate blocker (25). Ranolazine, amiodarone, and dronedar-
ne all display relatively rapid dissociation from the sodium
hannel, which contributes prominently to their atrial-
elective sodium channel blockade (26,27). We hypothe-
ized that a combination of open-state and inactivated-state
odium-channel blockade with rapid kinetics could produce
synergistic atrial-selective sodium-channel inhibition and
hus be effective against AF without producing significant
lectrophysiological effects in the ventricles. After validation
f this hypothesis (11), we considered the combination of
ronedarone and ranolazine, in that dronedarone is a
ongener of amiodarone with far fewer adverse effects and a
imilar electrophysiological profile. The results of the
resent study provide validation of this concept as well,
resenting further evidence in support of the hypothesis that
combination of predominantly open-state and inactivated-
tate blockers of the sodium channel can lead to synergistic
ffects to selectively inhibit INa-dependent parameters and
hus exert potent atrial-selective actions to terminate and
Effects of Ranolazine (5 mol/l), Dronedarone (Atrial Excitability and Induction of ACh-MediateCanine Coronary-Perfuse Right Atria
Table 1
Effects of Ranolazine (5 mol/l), D
Atrial Excitability and Induction of A
Canine Coronary-Perfused Right Atr
Protocol APD90 (ms) ER
Control 198 7 153
Ranolazine (5 mol/l) 210 10* 181
Dronedarone (10 mol/l) 202 9 171
Ranolazine  dronedarone 212 11* 211
ACh (1 mol/l) 41 6 52
Ranolazine (5 mol/l)  ACh 52 6† 72
Dronedarone (10 mol/l)  ACh 45 5 59
Ranolazine  dronedarone  ACh 67 14†‡ 99
APD90 and ERP data presented were obtained from the pectinate m
*p  0.05 versus control. †p  0.05 versus ACh (10 mol/l) alone. ‡p
ACh acetylcholine; AF atrial fibrillation; APD90 action potentia
refractory period.
ffects of Ranolazine (5 mol/l), Dronedarone10 m l/l), and Their Co bination to Terminateersistent ACh-Mediated AF a d Preventts Reinduction in t Isolated Canineo onary-Perfused Right Atria
Table 2
Effects of Ranolazine (5 mol/l), Dronedarone
(10 mol/l), and Their Combination to Terminate
Persistent ACh-Mediated AF and Prevent
Its Reinduction in the Isolated Canine
Coronary-Perfused Right Atria
Protocol
Termination of
Persistent AF
Prevention of
AF Reinduction
ACh (1 mol/l) 0% (0/10) —
ACh  ranolazine (5 mol/l) 20% (1/5) 100% (1/1)
ACh  dronedarone (10 mol/l) 17% (1/6) 0% (0/1)
ACh  ranolazine  dronedarone 60% (6/10) 100% (6/6)abbreviations as in Table 1.revent the induction and reinduction of AF (Table 1). The
ombination of the 2 drugs is expected to act synergistically
ecause the sodium channel is inhibited via 2 independent
echanisms. Note that although there are INa blockers that
an inhibit both open and inactivated sodium channels to a
imilar extent (e.g., quinidine or disopyramide), these agents
ause an unfavorable shift in the balance of inward and
utward currents, leading to QT prolongation, dispersion of
epolarization, and ventricular proarrhythmia. The slow
issociation of these drugs from the sodium channel can also
ead to a pronounced slowing of conduction, contributing to
he development of ventricular arrhythmias. In contrast,
anolazine as well as amiodarone and dronedarone have
apid unbinding kinetics from the sodium channel and
roduce a shift in the balance of currents that does not, or
ery rarely, cause ventricular proarrhythmia (26,27).
A major concern in the pharmacological management of
F agents is the risk for the induction of ventricular
rrhythmias and/or organ toxicity. Although amiodarone
nly rarely produces ventricular proarrhythmia and is gen-
rally safe in patients with structurally compromised ventri-
les, this agent causes extracardiac complications. Droneda-
one, a noniodinated derivative of amiodarone, is generally
onsidered to be safer compared with amiodarone in pa-
ients with AF (1). However, in patients with preexisting
evere congestive heart failure (New York Heart Association
unctional class III and IV), dronedarone has been reported
o worsen heart failure symptoms, leading to increased
ortality (4).
Clinical use of ranolazine, both acute and long term, has
ot been associated with serious adverse effects, not even in
atients with structural heart disease and no reported organ
oxicity (28). The rationale for combining dronedarone and
anolazine in the present study stems from the superiority of
ronedarone over amiodarone with respect to safety (1,3).
ike the combination of amiodarone and ranolazine (11),
he combination of dronedarone and ranolazine produces
otent atrial-selective anti-AF effects but is likely to be
M), and Their Combination onsistent AF in the Isolatedarone (10 M), and Their Combination on
ediated Persistent AF in the Isolated
)
Shortest S1 to S1 Interval
Permitting 1:1 Activation (ms)
Induction of
Persistent AF
130 10 0%
201 22* 0%
147 11* 0%
239 21 0%
56 7 100% (10/10)
94 11† 71% (5/7)
88 13† 83% (5/6)
‡ 120 24†‡ 10% (1/10)
region of coronary-perfused atria at a CL of 500 ms (n  5 to 15).
5 versus ranolazine plus ACh and dronedarone plus ACh.
nmeasured at 90% repolarization; CL cycle length; ERP effective10 d Perron d
Ch-M
ia
P (ms
 8
 11*
 11*
 16*
 9
 13†
 7
 18†
uscle
 0.0ssociated with fewer adverse effects and no organ toxicity.
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ental animal models, extrapolation to the clinic must be
one with great caution. It is noteworthy that our data were
btained acutely in “healthy” atrial and ventricular prepara-
ions. Most patients with AF have structural and electrical
ardiac abnormalities capable of modulating the pharmaco-
ogical response to chronic treatment. Although the vagally
ediated AF model used in the present study does not
ecapitulate all forms of clinical AF, the anti-AF efficacy of
ntiarrhythmic drugs previously studied using this model,
ncluding amiodarone, propafenone, lidocaine, and sotalol,
s consistent with the efficacy of these agents in the clinic
6,7). Finally, although dronedarone and ranolazine are
elatively safe and well tolerated when used individually
with the exception of dronedarone use in cases of advanced
eart failure [4]), the safety and tolerability of the combi-
ation of ranolazine and dronedarone is unknown.
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